TSHK advised in a RMB 300 million convertible bonds of Immunotech Biopharm Ltd (HKEx: 6978)
Eric Chow & Co. in Association with Commerce & Finance Law Offices (“TSHK”) recently represented Immunotech Biopharm Ltd (HKEx: 6978) (the “Company”) on its issuance of RMB300 million of convertible bonds under specific mandate, bearing an interest rate of 6% per annum and a maturity date of 3 years from the date of issuance (the “Convertible Bonds”). Subject to the adjustment events, the conversion price of the Convertible Bonds initially was HK$4.81 per conversion share.
TSHK represented the company in its listing on the Main Board of the Hong Kong Stock Exchange back in 2020. We have been their annual retained counsel since its listing. Immunotech Biopharm is a pre-revenue biotechnology company and is currently focusing on the research, development and commercialisation of T cell immunotherapy.
TSHK provided comprehensive legal services to Immunotech Biopharm Ltd throughout this transaction, including the drafting and reviewing of announcements and circular of the Company, comply with all the requirements under the Hong Kong Listing Rules, negotiation and liaison with the regulatory authorities.
TSHK team was led by Managing Partner Eric Chow, Partner Clement Jiang and Partner Brandon Chow, supported by Associate Carol Chan.